期刊文献+

糖眼明对糖尿病大鼠早期视网膜病变血管内皮细胞生长因子及细胞间黏附分子-1表达的影响 被引量:1

原文传递
导出
摘要 目的探讨中药制剂糖眼明对糖尿病大鼠视网膜血管内皮细胞生长因子(VEGF)及细胞问黏附分子-1(ICAM-1)表达影响,从而了解其对糖尿病视网膜病变的防治机理。方法制备糖尿病大鼠模型,分为正常组、糖眼明治疗组、糖尿病对照组及成模后3个月糖眼明治疗组。治疗3个月后糖眼明治疗组、糖尿病对照组及正常对照组取血测定血糖、血脂及糖化血红蛋白,取眼球制备视网膜病理切片,免疫组化染色观察10个高倍视野内糖尿病大鼠视网膜中 ICAM-1及 VEGF 的阳性细胞计数。同时成模后3个月糖眼明治疗组开始给予糖眼明灌胃,其余3组原方案继续灌服3个月,6个月后所有大鼠取血测定血糖、血脂及糖化血红蛋白,取眼球制备视网膜病理切片、免疫组化染色,观察10个高倍视野内糖尿病大鼠视网膜中 ICAM-1及 VEGF 的阳性细胞计数。结果3个月时,糖尿病对照组及糖眼明组较正常对照组大鼠视网膜 ICAM-1及 VEGF 的表达明显升高(P<0.05);糖眼明组较糖尿病对照组明显减少(P<0.05)。6个月后,糖尿病对照组、糖眼明组及3个月糖眼明组较正常对照组大鼠视网膜 ICAM-1及 VEGF的表达进一步升高(P<0.05);糖眼明组及3个月糖眼明组较糖尿病对照组明显减少(P<0.05);且糖眼明组较3个月糖眼明组明显减少(P<0.05);6个月后与3个月时比较,除正常组无明显变化外,糖尿病对照组及糖眼明组均较3个月时明显升高(P<0.05)。结论糖眼明可以明显抑制糖尿病大鼠视网膜ICAM-1及 VEGF 的表达。
出处 《国际中医中药杂志》 2007年第5期266-269,共4页 International Journal of Traditional Chinese Medicine
基金 河北省中医药管理局基金资助(No:2006027)
  • 相关文献

参考文献9

  • 1戴超,卞修武,史景泉.诺帝抑制糖尿病大鼠视网膜VEGF和iNOS的表达及意义[J].第三军医大学学报,2005,27(12):1232-1235. 被引量:13
  • 2张均.现代药理实验方法学.北京:北京医科大学、中国协和医科大学联合出版社,1998:981.
  • 3于德民,吴锐,尹潍,袁咏.实验性链脲佐菌素糖尿病动物模型的研究[J].中国糖尿病杂志,1995,3(2):105-109. 被引量:425
  • 4Nozaki M, Ogura Y, Hirabayashi Y, et al. Enhanced expression of adhsi-on molecules of the retinal vascular endothelium in spontaneous diabetic rats. Ophthalmic Rea, 2002, 34 (3): 158.
  • 5Mcleod DS, Lefer DJ, Merges C, et al. Enhanced expression of intracellular adhesion molecule-1 and P-seletin in the diabetic human retina and choroids. AmJPathol, 1995, 147 (3): 642-653.
  • 6杨婴,何守志,刘艳芳.糖尿病早期大鼠视网膜微血管改变的形态学研究[J].中华眼科杂志,1997,33(3):230-232. 被引量:16
  • 7Takagi H, Oh H, Otani A, et al. Molecular mechanisms of retinal nerovascu- larization in diabetic retinopathy. International Congress Series, 2004, 1262: 160-163.
  • 8Cukiernik M, Hileeto D, Evans T, et al. Vascular endothelial growth factor in diabetes induced early retinal abnormalities. Diabetes Res ClinPrac, 2004, 65 (3): 197-208.
  • 9Ayalasomayajula cyclooxygenase-2 SP, Kompella UB. Celecoxib, a selective inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model. Eur J Pharmcol, 2003, 458 (3): 283-289.

二级参考文献11

  • 1张惠蓉,眼微循环及其相关疾病,1993年,19页
  • 2Takagi H, Oh H, Otani A, et al. Molecular mechanisms of retinal neovascularization in diabetic retinopathy [ J ]. International Congress Series,2004,1262: 160 - 163.
  • 3Cukiernik M, Hileeto D, Evans T, et al. Vascular endothelial growth factor in diabetes induced early retinal abnormalities [J]. Diabetes Res Clin Prac,2004,65(3) : 197 - 208.
  • 4Scatia A, Pechan P, Lukason M, et al. Inhibition of retinal neovascularization by intraocular gene delivery of soluble VEGF receptors [ J ]. Mol Ther, 2004,9(Suppl 1) :S198.
  • 5Marano R J, Wimmer N, Kearns P S, et al. Inhibition of in vitro VEGF expression and choroidal neovascularization by synthetic dendrimer peptide mediated delivery of a sense oligonucleotide[J]. Exp Eye Res, 2004,79(4) : 525 - 535.
  • 6Berkowitz B A, Luan H, Gupta R R, et al. Regulation of the early subnormal retinal oxygenation response in experimental diabetes by inducible nitric oxide synthase[J]. Diabetes, 2004,53(1): 173 - 178.
  • 7Cukiernik M, Hileeto D, Downey D, et al. The role of the sodium hydrogen exchanger-1 in mediating diabetes-induced changes in the retina[J]. Diabetes Metab Res Rev, 2004,20(1): 61 - 71.
  • 8Ayalasomayajula S P, Kompella U B. Celecoxib, a selective cyclooxygenase - 2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin - induced diabetic rat model[J].Eur J Pharmcol, 2003,458 (3) : 283 - 289.
  • 9Takeda M, Mori F, Yoshida A, et al. Constitutive nitric oxide synthase is associated with retinal vascular peimeability in early diabetic mrs[J]. Diabetologia, 2001,44(8) : 1043 - 1050.
  • 10Rota R, Chiavaroli C, Garay R P, et al. Reduction of retinal albumin leakage by the antioxidant calcium dobesilate in streptozotocin - diabetic rats [J]. Eur J Pharmacol, 2004, 495(2) : 217 - 224.

共引文献451

同被引文献3

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部